SLC12A5 and central nervous system cancer: In this study, we reported the identification of genome‐structurally altered SLC12A5 based on Hi‐C (high throughput chromosome conformation capture) data and it could function as a suppressor in glioma correlated with patient prognosis, GABAA receptor activity, immune‐enriched microenvironment and immunotherapy response.